METHOD FOR QUANTIFYING ACTIVITY OF INTRACELLULAR LIPID METABOLISM ENZYMES, KIT FOR QUANTIFYING ACTIVITY OF INTRACELLULAR LIPID METABOLISM ENZYMES, AND METHOD FOR SCREENING AGENT FOR CONTROLLING ACTIVITY OF LIPID METABOLISM ENZYMES

By introducing a lipid metabolic enzyme with a myristoylation sequence to translocate DGK isozymes to the membrane, the method allows for the measurement of intracellular activities, facilitating the development of therapeutic drugs for diseases involving these enzymes.

JP7577340B2Active Publication Date: 2024-11-05CHIBA UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021554159
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-24
Filing Date
2020-09-15
Publication Date
2024-11-05
Estimated Expiration
2040-09-15

AI Technical Summary

Technical Problem

Existing methods are unable to measure the intracellular activity of DGK isozymes other than DGKα, which is crucial for evaluating the effects of compounds on these enzymes within cells, as they cannot be constantly activated or strongly stimulated.

Method used

Introduce a lipid metabolic enzyme with a myristoylation sequence, such as a specific base sequence, into cells to translocate them to the membrane, allowing for the measurement of intracellular activity using liquid chromatography mass spectrometry.

Benefits of technology

This method enables the specific measurement of intracellular activities of nine DGK isozymes, accelerating the development of therapeutic drugs for various diseases by overcoming the rate-limiting stage of enzyme activity evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577340000002
    Figure 0007577340000002
  • Figure 0007577340000003
    Figure 0007577340000003
  • Figure 0007577340000004
    Figure 0007577340000004
Patent Text Reader

Abstract

Some types of DGK isozymes have been difficult to measure the activities thereof in cells. A method for measuring the activity of a diacylglycerol kinase comprises the steps of: introducing a diacylglycerol kinase having a myristoylation sequence into a cell; and measuring the amount of phosphatidic acid in the cell. The diacylglycerol kinase having a myristoylation sequence is at least one nucleotide sequence selected from the nucleotide sequences (1) to (3). (1) A nucleotide sequence represented by SEQ ID NO: 1; (2) a nucleotide sequence having 90% or more identity to the nucleotide sequence represented by SEQ ID NO: 1; and (3) a nucleotide sequence having such a structure that 5 or less nucleotides in a nucleotide sequence comprising the nucleotide sequence represented by SEQ ID NO: 1 are deleted, substituted and / or added.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for measuring intracellular lipid metabolic enzyme activity and a substance for measuring intracellular lipid metabolic enzyme activity. [Background technology]

[0002] In order to develop a drug, in addition to evaluating the compound in vitro (in a test tube), it is essential to verify the effect of the target enzyme in cells. The only conventional method for measuring intracellular diacylglycerol kinase (a lipid metabolism enzyme, hereinafter sometimes referred to as "DGK") activity was developed by the inventors using a liquid chromatography mass spectrometer (Non-Patent Document 1). Here, kinase is a general term for enzymes in biochemistry that transfer (phosphorylate) phosphate groups from molecules with high-energy phosphate bonds such as ATP to substrates or target molecules, and is also called phosphorylation enzymes. However, the only one that has been successful in measuring the change in DGK isozyme-specific activity when an inhibitory compound is added is a constitutively active mutant of the α isozyme of DGK (a mutant lacking the N-terminal activity control (inhibitory) region) (Non-Patent Document 2). Constitutively active mutants of the other nine isozymes and a method for potent activity stimulation are not known, and therefore it has been impossible to measure the activity of the other nine isozymes in cells. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Mizuno, S. et al. FEBS Open Bio, 2, 267-272 (2012) [Non-Patent Document 2] Liu, K. et al. Journal of Lipid Research., 57, 368-379 (2016) Summary of the Invention [Problem to be solved by the invention]

[0004] To measure DGK isozyme-specific activity, there must be an increase in activity in cells that overexpress the DGK isozyme. The effect of a compound is then measured by inhibiting this increase. However, until now, only a constitutively active mutant of DGKα has shown an increase in activity in overexpressed cells, and no other isozymes have been detected. This is because the other isozymes are not constitutively active. [Means for solving the problem]

[0005] In order to solve the above problems, according to one aspect of the present invention, a method for measuring intracellular lipid metabolic enzyme activity comprises the steps of introducing a lipid metabolic enzyme having a myristoylation sequence into a cell and measuring the amount of phosphatidic acid in the cell.

[0006] In the above-mentioned measurement method, it is desirable that the lipid metabolic enzyme having a myristoylation sequence has any one of the following base sequences (1) to (3). (1) a nucleotide sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO:1 have been deleted, substituted and / or added.

[0007] According to another aspect of the present invention, the substance for measuring lipid metabolic enzyme activity contains a lipid metabolic enzyme having a myristoylation sequence. In the above-mentioned substance for measuring lipid metabolic enzyme activity, it is preferable that the lipid metabolic enzyme having a myristoylation sequence has any one of the following base sequences (1) to (3). (1) a nucleotide sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO:1 have been deleted, substituted and / or added. Effect of the Invention

[0008] This method makes it possible to specifically measure the intracellular activity of nine isozymes other than DGKα, which was previously impossible. There are many diseases in which the nine DGK isozymes are involved (e.g., various cancers, epilepsy, obsessive-compulsive disorder, bipolar disorder, autoimmune diseases, cancer immunity, cardiac hypertrophy, hypertension, diabetes, Parkinson's disease, Alzheimer's disease, etc.), and when developing treatments for these diseases (DGK isozyme activity regulators), it becomes possible to evaluate the effects within cells, overcoming the rate-limiting step in development and greatly accelerating the progress of development. Several pharmaceutical companies have already shown interest. Development of DGK isozyme activity regulators is progressing on a global scale, and many pharmaceutical companies are likely to show interest. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 is a diagram showing the principle of the diacylglycerol kinase assay method of the present invention. [Diagram 2] FIG. 1 shows the expression levels of AcGFP-DGKζ and Myr-AcGFP-DGKζ in COS-7 cells. [Diagram 3] FIG. 1 shows the effect of AcGFP-DGKζ and Myr-AcGFP-DGKζ on the amount of PA molecular species in COS-7 cells. [Figure 4] FIG. 1 shows the expression levels of Myr-AcGFP-DGKζ and Myr-AcGFP-DGKζ-KD in COS-7 cells. [Diagram 5] FIG. 1 shows the effect of Myr-AcGFP-DGKζ and Myr-AcGFP-DGKζ-KD on the amount of PA molecular species in COS-7 cells. [Figure 6] FIG. 1 shows the distribution of Vector, DGKζ, Myr-DGKζ, and Myr-DGKζ-KD in COS-7 cells. [Figure 7] FIG. 1 shows the results of cell fractionation using ultracentrifugation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Hereinafter, examples of embodiments of the present invention will be described, but the embodiments of the present invention are not limited to the examples of embodiments described below. Myristoylation (addition of myristic acid (hydrophobic anchor) to proteins) (Figure 1) transfers the protein to the membrane (hydrophobic). Furthermore, while DGK isozymes are localized in the cytoplasm, their substrate (diacylglycerol (DG)) is present in the cell membrane. Furthermore, the wild type, a constitutively active mutant of DGKα, is localized in the cytoplasm. Therefore, we thought that by myristoylating DGK isozymes, we could transfer them to the membrane and make them in a constitutively active state, thereby forcibly increasing the activity of DGK isozymes, and then detect the activity using a liquid chromatography mass spectrometry device (Figure 1). We then confirmed the increase in activity and solved the previous problem.

[0011] That is, according to one aspect of the present invention, a method for measuring lipid metabolic enzyme activity comprises the steps of introducing a lipid metabolic enzyme having a myristoylation sequence into a cell and measuring the amount of phosphatidic acid in the cell.

[0012] In the above-mentioned measurement method, it is desirable that the lipid metabolic enzyme having a myristoylation sequence has any one of the following base sequences (1) to (3). (1) a nucleotide sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO:1 have been deleted, substituted and / or added.

[0013] According to another aspect of the present invention, the substance for measuring lipid metabolic enzyme activity contains a lipid metabolic enzyme having a myristoylation sequence.

[0014] In the above-mentioned substance for measuring lipid metabolic enzyme activity, it is preferable that the lipid metabolic enzyme having a myristoylation sequence has any one of the following base sequences (1) to (3). (1) a nucleotide sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO:1 have been deleted, substituted and / or added. EXAMPLES

[0015] 1. Summary Inhibitors specific to diacylglycerol kinase (DGK)ζ could be promising anticancer drugs to activate cancer immunity. Although detection of intracellular activity of target enzymes is essential for in vitro assays as well as drug screening, it is difficult to detect the activity of DGKζ in cells. In this study, we generated AcGFP-DGKζ cDNA with an N-myristoylation sequence at the 5' end (Myr-AcGFP-DGKζ) to bring the target DGKζ closer to the membrane. Using LC-MS / MS, we showed that Myr-AcGFP-DGKζ, but not AcGFP-DGKζ without the myristoylation sequence, increased the production of several phosphatidic acid (PA) molecular species. In contrast to Myr-AcGFP-DGKζ, its inactive mutant did not show increased PA production. This suggests that the increase in PA production depends on the activity of DGK. This method will be useful for selecting chemicals for the development of drugs targeting DGKζ and may also be applicable to a variety of soluble (non-membrane-bound) lipid metabolism enzymes, including other DGK isozymes.

[0016] 2. Introduction Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DG) and converts it to phosphatidic acid (PA). DG is an activator of protein kinase Cs (PKCs), Unc-13, chimaerin, and Ras guanyl nucleotide releasing protein. Meanwhile, PA regulates various pathophysiologically important enzymes such as mammalian target of rapamycin, atypical PKC, C-Raf, Ras GTPase activating protein, son of sevenless (guanine nucleotide exchange factor), and phosphatidic inositol-4-phosphate kinase. Thus, DGK is known to regulate the balance of two lipid second messengers, DG and PA, and to be involved in various physiological and pathological events.

[0017] Mammalian DGKs are composed of 10 isozymes (α-κ) and are divided into five groups according to their structural features: type I (α, β, and γ), II (δ, η, and κ), III (ε), IV (ζ, ι), and V (θ) [1-4]. In addition to the catalytic domain, type IV DGK isozymes (ζ, ι) have two C1 domains at the N-terminus, a MARCKS (myristoylated alanine-rich C-kinase substrate) domain at the C-terminus, four ankyrin repeats, and a PDZ domain.

[0018] Among them, DGKζ is a multifunctional protein. In addition to DGKα (type I), DGKζ acts as an attenuator of T cell receptor (TCR) signaling and T cell activation. Thus, DGKζ-deficient T cells show enhanced response to TCR stimulation ex vivo and in vivo. These results suggest that DGKζ-specific inhibitors could be promising anticancer drugs by activating TCR signaling and, as a result, cancer immunity. It has been reported that deficiency of DGKζ leads to reduced protection against obesity and insulin resistance. In addition, DGKζ associates with insulin receptor substrate-1 and regulates GLUT-4 translocation in adipocytes. Furthermore, it has been reported that the action of DGKζ reduces DG mass and attenuates cell proliferation. DGKζ regulates the leptin signaling pathway in the hypothalamus. Furthermore, this isozyme promotes neurite outgrowth in NIE-115 neuroblastoma cells. Recently, we demonstrated that DGKζ generates 16:0 / 16:0-PA species and promotes retinoic acid / serum starvation-induced neurite outgrowth in Neuro-2a neuroblastoma cells. Thus, DGKζ is suggested to play a role in neurite growth during the initial and early stages of neuronal differentiation. DGKζ-dependent conversion of DG to PA plays an important role in the maintenance of dendrites. Furthermore, this isozyme suppresses cardiac hypertrophy induced by Gq protein-coupled receptor agonists and regulates fiber size during skeletal muscle remodeling.

[0019] DGKζ is recognized as an attractive drug target because of its physiological and pathological importance. Detection of intracellular activity of target enzymes is essential for drug screening in addition to in vitro assays. However, detection of intracellular activity of DGKζ is difficult. DGKζ is widely distributed in the nucleus and cytoplasm. To generate PA, DGKζ needs to be translocated to the membrane. However, DGKζ stimulation causes its exclusive membrane localization, but the mechanism has not been elucidated. Since an active mutant of DGKα that lacks the negative regulatory domain and translocates to the membrane with substrates can be generated, the inventors have already established its activity assay in cells. On the other hand, an active mutant of DGKζ has not yet been established.

[0020] Myristoylation is thought to promote membrane translocation. In this study, we generated AcGFP-DGKζ cDNA carrying the N-myristoylation sequence of c-Src at the 5' end (myristoylated (Myr-)AcGFP-DGKζ) to translocate the target DGKζ to the membrane. Using Myr-AcGFP-DGKζ and our recently established liquid chromatography (LC)-tandem mass spectrometry (MS / MS) DGK assay, we attempted to detect the activity of DGKζ in cells.

[0021] 3. Materials and Methods (1) Myr-AcGFP-DGKζ cDNA construct To generate pMyr-AcGFP vector, an N-myristoylation sequence (5'-atggggagtagcaagagcaagcctaaggaccccagccagcgc-3') (SEQ ID NO: 1) was inserted into the AcGFP translation initiation site in pAcGFP-C1 vector (Takara Clontech). To construct pMyr-AcGFP-DGKζ, a PCR fragment encoding DGKζ cDNA (UniProt accession ID: DGKζ Q13574-2), p3×FLAG-CMV-human DGKζ

[38] was ligated into the EcoR I-Sal I sites of pMyr-AcGFP vector. An inactive mutant of DGKζ (DGKζ-KD) was generated by PCR-based site-directed mutagenesis (Gly-355 to Asp(G355D)).

[0022] 4. Cell Culture and Transfection COS-7 cells were maintained in Dulbecco's Modified Eagle Medium (Wako Pure Chemical Industries) supplemented with 10% fetal bovine serum (Biological Industries, Beit-Haemek, Israel), 100 units / ml penicillin, and 100 μg / ml streptomycin (Wako Pure Chemical Industries) in an atmosphere containing 5% CO2 at 37°C. Cells were transfected with PolyFect reagent (Qiagen) as described by the manufacturer.

[0023] (1) Western blotting COS-7 cell lysates (20 μg) were separated by SDS-polyacrylamide gel electrophoresis, and anti-GFP (Santa Cruz Biotechnology) and anti-mouse IgG antibodies (Jackson ImmunoResearch Laboratories) were used for Western blotting.

[0024] (2) Confocal microscope Twenty-four hours after transfection of pAcGFP, pAcGFP-DGKζ, pMyr-AcGFP-DGKζ, and pMyr-AcGFP-DGKζ-KD, COS-7 cells were fixed with 4% paraformaldehyde. Coverslips were fixed with Vectashield (Vector Laboratories). Fluorescent images were acquired using an Olympus FV1000-D (IX81) confocal laser scanning microscope (Olympus) equipped with a UPLSAPO with 60× 1.35 NA oil at room temperature. AcGFP fluorescence was excited at 488 nm. Images were acquired using FV-10 ASW software (Olympus).

[0025] (3) Cellular fractionation COS-7 cells (60 mm dishes) expressing AcGFP alone, AcGFP-DGKζ, Myr-AcGFP-DGKζ, or Myr-AcGFP-DGKζ-KD were lysed in 500 μl of ice-cold lysis buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, Complete TM The cells were dissolved in EDTA-suspended protease inhibitors (Roche Diagnostics (Rotkreuz), 1 tablet / 50 ml) and 1 mM phenylmethylsulfonyl fluoride. To remove cell debris, the cell lysate was centrifuged at 350 g for 5 min at 4°C. The resulting supernatant was centrifuged at 100,000 g for 1 h at 4°C. The supernatant and pellet were analyzed by SDS-PAGE and Western blotting.

[0026] (4) LC-MS / MS 24 hours after transfection with pMry-AcGFP, pMry-AcGFP-DGKζ, or pMry-AcGFP-DGKζ-KD, cells were harvested with phosphate-buffered saline. Total lipids were extracted from cells by the Bligh and Dyer method. Briefly, 2 ml of methanol and 700 ml of chloroform were added to 700 μl of sample. 100 ng of 28:0-PA (Avanti Polar Lipids) was added as an internal standard. 100 μl of 3 M HCl was added to the sample to increase the recovery of acidic phospholipids. After the addition of HCl, the sample was vortexed for 30 s. After incubation at room temperature for 30 min, 1 ml of water was added and vortexed for 30 s, followed by 1 ml of chloroform and vortexing for 30 s. To separate the phases, the sample was centrifuged at 1000 × g for 10 min. The lower phase containing the extracted lipids was transferred to a new vial. The lipid-containing solvent was dried under nitrogen gas, and the extracted lipids were reconstituted in 100 μl of chloroform / methanol (2:1, v / v). The extracted lipids (10 μl) were separated as described above on an LC system (Shimadzu) using a Unison UK-Silica column (3 μl, 150 × 2.0 mm 1.d., Imtakt). The LC system was controlled with Analyst software (AB SCIEX). The gradient used was solvent A (chloroform / methanol (89:10) containing 0.28% ammonia) and solvent B (chloroform / methanol / water (55:39:5) containing 0.28% ammonia). The gradient elution program was 20% B for 5 min, 20% to 30% B in 10 min, 30% to 60% B in 25 min, 60% B in 5 min, 60% to 20% B in 1 min, followed by 20% B in 14 min. The flow rate was 0.3 ml / min, and the chromatography was performed at 25°C.

[0027] The LC system consisted of a triple quadrupole tandem mass spectrometer with a turbospray ionization source, Triple Quad TMThe system was connected online to a 4500 (AB SCIEX, Framingham). The experimental conditions were as follows: ion spray voltage—4500 V, curtain gas—30 psi, collision gas—6 psi, temperature 300°C, deflocculation voltage—160 V, entrance potential—10 V, collision energy 42 V, collision cell exit potential—11 V, ion source gas I 70 psi, ion source gas II 30 psi. PA molecular species were detected by multiple reaction monitoring (MRM). The ionized PA species ([MH] ― ) were separated in the first quadrupole (Q1). The resulting ion (m / z 153 in negative ion mode) was then fragmented in Q2 by collision-induced dissociation and reselected in Q3. Each phospholipid species is represented in the form X:Y, where X is the total number of carbon atoms and Y is the total number of double bonds in both acyl chains of the phospholipid.

[0028] (5) Statistical analysis Data are expressed as the mean ± SD and analyzed by one-way ANOVA followed by Turkey post hoc test for multiple comparisons using Prism 8 (GraphPad Software, San Diego, CA, USA).

[0029] (6) Results (a) Subcellular localization of Myr-AcGFP-DGKζ We first confirmed the intracellular localization of Myr-AcGFP-DGKζ expressed in COS-7 cells by confocal microscopy. Non-myristoylated AcGFP-DGKζ was widely distributed in the cytoplasm, cell nucleus, and perinuclear regions. However, Myr-AcGFP-DGKζ was mainly localized to the cell membrane and perinuclear regions (Fig. 6). These results suggest that DGKζ myristoylation induces membrane localization. An inactive mutant of DGKζ (Mry-AcGFP-DGKζ-KD) was also distributed to the cell membrane and perinuclear regions (Fig. 6). Thus, it was suggested that the induction of membrane localization is independent of DGK activity.

[0030] To verify whether membrane localization depends on myristoylation, we next performed cell fractionation using ultracentrifugation. AcGFP-DGKζ was only partially (approximately 60%) recovered in the 100,000 g ppt (membrane) fraction (Figure 7). On the other hand, Myr-AcGFP-DGKζ and Myr-AcGFP-DGKζ-KD were completely (100%) recovered in the 100,000 g ppt (membrane) fraction (Figure 7). This suggests that myristoylation exclusively induces the membrane localization of AcGFP-DGKζ.

[0031] (b) Detection of PA production by Myr-AcGFP-DGKζ in cells Using Myr-AcGFP-DGKζ and a recently developed LC-MS-based DGK assay, we measured DGKζ activity in cells. COS-7 cells were transfected with either pAcGFP alone (vector), pAcGFP-DGKζ, or pMyr-AcGFP-DGKζ. 24 hours after transfection, the cells were subjected to SDS-PAGE and Western blotting with anti-GFP antibody, as shown in Figure 2. We confirmed that the expression levels of AcGFP-DGKζ and Myr-AcGFP-DGKζ were almost the same (Figure 2).

[0032] Figure 3 shows the LC-MS / MS quantification of the PA molecular species in COS-7 cells overexpressing AcGFP alone, AcGFP-DGKζ, or Myr-AcGFP-DGKζ. LC-MS / MS analysis revealed that Myr-AcGFP-DGKζ significantly increased the production of PA molecular species (Figure 3). Values ​​are expressed as the mean ± SD of four independent experiments. *p<0.05, **p<0.01. In Figure 3, the leftmost bar shows the amount of PA molecular species in AcGFP alone (vector), the second bar shows the amount of PA molecular species in AcGFP-DGKζ, and the third bar shows the amount of PA molecular species in Myr-AcGFP-DGKζ.

[0033] In particular, the production of 30:1-PA (48% increase), 30:0-PA (50% increase), 32:3-PA (43% increase), 32:2-PA (45% increase), 32:1-PA (42% increase), 32:0-PA (33% increase), 38:6-PA (39% increase), and 38:5-PA (39% increase) was significantly increased in COS-7 cells expressing Myr-AcGFP-DGKζ compared to cells expressing vector alone (Fig. 3, Table 1). However, non-myristoylated AcGFP-DGKζ did not affect the production of PA molecular species (Fig. 3). Here, experimental data for DGKζ are shown, but myristoylation also increases the production of PA with DGK isozymes other than DGKζ. In cells expressing only the vector, PA species are thought to be generated from multiple pathways, such as de novo synthesis, hydrolysis of phosphatidylcholine by phospholipase D, and phosphorylation of DG by endogenous DGK isozymes.

[0034] [Table 1]

[0035] To confirm whether the increase in the production of PA molecular species was due to the activity of DGKζ, the inventors next confirmed the effect of Myr-AcGFP-DGKζ-KD (inactive form; KD stands for Kinase-dead). COS-7 cells were transfected with either pAcGFP alone (vector), pAcGFP-DGKζ, or pMyr-AcGFP-DGKζ. 24 hours after transfection, the cells were subjected to SDS-PAGE and Western blotting using an anti-GFP antibody, as shown in Figure 4. The expression level of Myr-AcGFP-DGKζ-KD was almost the same as that of Myr-AcGFP-DGKζ (Figure 4). The amounts of the major PA molecular species (30:1-PA, 30:0-PA) in COS-7 cells overexpressing AcGFP alone, Myr-AcGFP-DGKζ, and Myr-AcGFP-DGKζ-KD were quantified by LC-MS / MS. Values ​​are shown as the mean ± SD of four independent experiments. *p<0.05, **p<0.01. The leftmost bar shows the amount of PA molecular species in AcGFP alone (vector), the second bar shows the amount of PA molecular species in Myr-AcGFP-DGKζ, and the third bar shows the amount of PA molecular species in Myr-AcGFP-DGKζ-KD. The results of LC-MS / MS of 30:1-PA and 30:0-PA, whose expression was significantly increased in Myr-AcGFP-DGKζ, are shown (Fig. 5, Table 1). The production of 30:1-PA and 30:0-PA molecular species was significantly increased in Myr-AcGFP-DGKζ, but not in Myr-AcGFP-DGKζ-KD (Fig. 5), suggesting that the increase in PA production is dependent on DGKζ activity. These results indicate that the increase in the production of individual PA molecular species, such as 30:1-PA and 30:0-PA, caused by Myr-AcGFP-DGKζ-expressing COS-7 cells can be easily detected.

[0036] (7) Consideration In this study, the inventors have provided a new method to detect DGKζ activity in cells. It has been difficult to detect DGK activity in cells so far. In fact, non-myristoylated DGKζ did not show a large increase in the production of individual PA molecular species (Figure 3). To overcome this difficulty, we generated myristoylated AcGFP-DGKζ. Myristoylation translocates AcGFP-DGKζ to the cell membrane (Figure 6) where its substrates are present. As expected, the inventors succeeded in detecting the production of PA molecular species derived from Myr-AcGFP-DGKζ activity, such as 30:1-PA and 30:0-PA (Figure 3, Table 1). These results suggest that Myr-AcGFP-DGKζ may act as an active mutant.

[0037] About 60% of non-myristoylated AcGFP-DGKζ was detected in the 100,000 g ppt (membrane) fraction (Fig. 7), whereas nearly 100% of Myr-AcGFP-DGKζ was detected in the 100,000 g ppt fraction. Furthermore, confocal microscopy demonstrated that myristoylation enhanced the membrane localization of DGKζ (Fig. 6). From the above, it can be said that myristoylation certainly enhances the membrane localization. Although about half of AcGFP-DGKζ was in the membrane fraction, it did not induce a significant increase in PA molecular species (Fig. 3). Therefore, it is considered that AcGFP-DGKζ cannot efficiently utilize the DG present there due to its weak interaction with the membrane.

[0038] Previously, we reported that DGKζ mainly produces 16:0 / 16:0-PA in Neuro-2a cells during retinoic acid- and serum starvation-induced neuroblastoma cell differentiation. In this study, we showed that a wide range of PA molecular species was increased in cells expressing Myr-AcGFP-DGKζ (Fig. 3). Myristoylation induces membrane translocation of proteins, and DGKζ may have randomly translocated to the membrane. Indeed, Myr-AcGFP-DGKζ was widely distributed in the plasma membrane and perinuclear regions (Fig. 6). In neuroblastoma cells, DGKζ is partially localized to the plasma membrane during retinoic acid-induced cell differentiation. Furthermore, insulin receptor and TCR stimulation induce plasma membrane localization of DGKζ. Thus, random membrane localization of Myr-AcGFP-DGKζ may lead to the production of a wide range of PA molecular species.

[0039] This newly developed method allows us to analyze the activity of DGKζ in a more biological condition (on cell membrane) compared with the in vitro mixed micelle model, and therefore is useful for selecting candidate compounds to be initially screened in vitro for the development of drugs targeting DGKζ, because detection of the cellular activity of the target enzyme is necessary in addition to in vitro assays to develop good drugs.

[0040] Currently, there are no useful DGKζ-selective inhibitors. In addition, commercially available DGK inhibitors, R59022 and R59949, could not effectively inhibit DGKζ. Therefore, the inventors could not verify an assay system suitable for inhibitor assay using tool compounds. However, the inventors demonstrated that the production levels of 30:1-PA and 30:0-PA molecular species of Myr-AcGFP-DGKζ-KD, which is equivalent to the enzyme inhibited by the chemical, are significantly lower than those of Myr-AcGFP-DGKζ (Figure 5). Therefore, this system is likely to be suitable for compound selection.

[0041] This new method is also applicable to other DGK isozymes. Many isozymes are soluble (non-membrane bound) and distributed in the cytosol and nucleus. Therefore, DGK isozymes need to translocate from the cytosol to the membrane where substrates are abundant in order to make their activity more visible. As was the case for DGKζ (Figure 3), simply overexpressing other DGK isozymes would not show an increase in PA production. Therefore, membrane localization of DGK isozymes is applicable to detecting their intracellular activity. Furthermore, the experimental method provided in this study is likely to be applicable to other lipid metabolism enzymes that are soluble or distributed in the cytosol.

[0042] In conclusion, we have developed a new method to detect DGKζ activity in cells. This new method will be useful for compound selection after initial in vitro screening for the development of drugs targeting DGKζ. Furthermore, this method will be applicable to various soluble (non-membrane-bound) lipid metabolism enzymes, including other DGK isozymes. [Industrial Applicability]

[0043] INDUSTRIAL APPLICABILITY The present invention can be industrially applied as a method for measuring intracellular lipid metabolic enzyme activity and a substance for measuring intracellular lipid metabolic enzyme activity.

Claims

1. A method for quantitatively measuring intracellular lipid metabolic enzyme activity, comprising the steps of: introducing a lipid metabolic enzyme having a myristoylation sequence and an inactive mutant of the lipid metabolic enzyme having a myristoylation sequence into a cell; and quantitatively measuring activity by comparing the amount of phosphatidic acid in a cell into which the lipid metabolic enzyme having the myristoylation sequence has been introduced with the amount of phosphatidic acid in a cell into which the inactive mutant of the lipid metabolic enzyme having the myristoylation sequence has been introduced.

2. The method for quantitatively measuring intracellular lipid metabolic enzyme activity according to claim 1, characterized in that the lipid metabolic enzyme having the myristoylation sequence and the inactive mutant of the lipid metabolic enzyme having the myristoylation sequence have an amino acid sequence encoded by any one of the following base sequences (1) to (3): (1) a base sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO: 1 have been deleted, substituted and / or added.

3. A kit for quantitatively measuring intracellular lipid metabolic enzyme activity, comprising a substance for measuring soluble lipid metabolic enzyme activity containing a lipid metabolic enzyme having a myristoylation sequence, and a substance for measuring soluble lipid metabolic enzyme activity containing an inactive mutant of a lipid metabolic enzyme having a myristoylation sequence.

4. The kit for quantitatively measuring intracellular lipid metabolic enzyme activity according to claim 3, characterized in that the lipid metabolic enzyme having a myristoylation sequence and the inactive mutant of the lipid metabolic enzyme having a myristoylation sequence have an amino acid sequence encoded by any one of the following base sequences (1) to (3): (1) a base sequence represented by SEQ ID NO:1; (2) a nucleotide sequence having 90% or more homology to the nucleotide sequence represented by SEQ ID NO:1; (3) A base sequence in which up to 5 bases of the base sequence represented by SEQ ID NO: 1 have been deleted, substituted and / or added.

5. A method for screening for a lipid metabolic enzyme activity regulator, comprising the steps of: introducing into cells a lipid metabolic enzyme having a myristoylation sequence and an inactive mutant of the lipid metabolic enzyme having a myristoylation sequence; introducing into the cells candidate compounds for lipid metabolic enzyme activity regulators; quantifying the amount of phosphatidic acid produced in the cells; and quantifying the activity of the candidate compounds from changes in the amount of phosphatidic acid produced in each cell into which the candidate compounds have been introduced.

Citation Information

Patent Citations

  • controlled apoptosis

    JP1997503645A

  • Multiparameter FACS for detecting changes in cellular parameters and screening small molecule libraries

    JP2002512362A